… (15 mg/kg per day) in a subcutaneous xenograft model of human HCC growth using two …
to sorafenib was significantly less effective in inhibiting tumor growth (15.4% tumor growth …

… treatment with sorafenib plus another agent, such as erlotinib, … be verified in vivo using
animal models prior to their potential … an in vivo model of xenografts of PLC/PRF/5 tumor cells in …

… Sorafenib is the only chemotherapeutic agent currently approved for unresectable hepatocellular
carcinoma … potential chemomodulatory effects of I3C on sorafenib in HCC cells as well …

… vivo orthotopic model failed to demonstrate a synergistic anti-tumour effect of combination
treatment with erlotinib and sorafenib[… erlotinib with sorafenib treatment in HCC (SEARCH trial, …

… observed using the combination of sorafenib and erlotinib, a direct inhibitor of … benefits,
compared to sorafenib treatment in the orthotopic HCC model. … Animal models and experiments …

… of Sorafenib with AKT inhibitor compared to untreated control and to standard treatment,
Sorafenib… migration with significantly higher potency than Sorafenib. Similarly, apoptotic cell was …

… of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition of angiogenesis of
Sorafenib … antiblastics (Gemox, Folfox etc) or erlotinib in many phase II trials in advanced HCC …

… Hepatocellular carcinoma (HCC) is one of the most prevalent … A freely moving rat model was
designed for the current study … We established a dosage of sorafenib for the rats as 40 mg/kg…

… of sorafenib response in HCC, testing for VEGF-A serum levels was not found to be predictive
of sorafenib … A possible explanation for this is that the mechanism of action of sorafenib is …

… The inhibitory activity of gefitinib and erlotinib on HCC growth … in an orthotopic rat HCC
model mimicking chemoembolization, … Randomized phase III trial of sorafenib versus placebo in …